Aptamer Group Celebrates its AIM Listing Success
Aptamer Group celebrated its recent Admission to AIM on Friday evening, with an exclusive party at the Sora Sky bar in the Malmaison hotel, York.
This biotechnology company, based at York Science Park, has seen significant growth over the past year, with increases in team numbers to support a variety of ongoing partnerships with global pharmaceutical and life science companies, including AstraZeneca, Cancer Research UK, and Takeda.
Aptamer develops an oligonucleotide-based antibody alternative, Optimer®, that can be used in diagnostic tests and as drug delivery vehicles for a range of diseases, such as cancer. They are currently shortlisted for four awards at the upcoming BioNow award ceremony on March 31st, 2022: Technical Service Award, Response to COVID-19 Pandemic Award, Investment Deal of the Year Award and Company of the Year Award.
The Company listed on AIM at the end of December, following a fundraise of £10.8 million to support the next phase of their growth. They invited staff, shareholders and corporate partners who have supported the Group in their listing to the private event to mark the occasion.
Photo credit: Talia Kirkbride (@talia_k_photography)
